|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
Incidence and Mortality Worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ren JS, Masuyer E and Ferlay J:
Global estimates of cancer prevalence for 27 sites in the adult
population in 2008. Int J Cancer. 132:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Al-Madouj A, Eldali A and Al-zahrani AS:
Ten-Year Cancer Incidence: Among Nationals of the GCC States
(1998–2007). Gulf Center for Cancer Control and Prevention.
2011.https://www.moh.gov.bh/Content/Files/Publications/GCC%20Cancer%20Inci-dence%202011.pdfJanuary
7–2017
|
|
4
|
Kumar S, Burney IA, Al-Ajmi A and
Al-Moundhri MS: Changing trends of breast cancer survival in
sultanate of oman. J Oncol. 2011.3162432011.PubMed/NCBI
|
|
5
|
Al-Moundhri M, Al-Bahrani B, Pervez I,
Ganguly SS, Nirmala V, Al-Madhani A, Al-Mawaly K and Grant C: The
outcome of treatment of breast cancer in a developing country-Oman.
Breast. 13:139–145. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Simpson PT, Gale T, Fulford LG, Reis-Filho
JS and Lakhani SR: The diagnosis and management of pre-invasive
breast disease: Pathology of atypical lobular hyperplasia and
lobular carcinoma in situ. Breast Cancer Res. 5:258–262. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis-correlation in invasive breast
carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Allred DC: Ductal Carcinoma In Situ:
Terminology, Classification, and Natural History. J Natl Cancer
Inst Monogr. 2010:134–138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sharma GN, Dave R, Sanadya J, Sharma P and
Sharma KK: Various types and management of breast cancer: An
overview. J Adv Pharm Technol Res. 1:109–126. 2010.PubMed/NCBI
|
|
10
|
Kobayashi E, Ueda Y, Matsuzaki S, Yokoyama
T, Kimura T, Yoshino K, Fujita M, Kimura T and Enomoto T:
Biomarkers for screening, diagnosis, and monitoring of ovarian
cancer. Cancer Epidemiol Biomarkers Prev. 21:1902–1912. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Horta M and Cunha TM: Sex cord-stromal
tumors of the ovary: A comprehensive review and update for
radiologists. Diagn Interv Radiol. 21:277–286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Norris HJ and Jensen RD: Relative
frequency of ovarian neoplasms in children and adolescents. Cancer.
30:713–719. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Murray MJ and Nicholson JC: Germ cell
tumours in children and adolescents. Paediatrics Child Health.
20:109–116. 2010. View Article : Google Scholar
|
|
14
|
Cho KR and Shih IeM: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Williams TI, Toups KL, Saggese DA, Kalli
KR, Cliby WA and Muddiman DC: Epithelial Ovarian Cancer: Disease
etiology, treatment, detection and investigational gene,
metabolite, and protein biomarkers. J Proteome Res. 6:2936–2962.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McSherry EA, Donatello S, Hopkins AM and
McDonnell S: Molecular basis of invasion in breast cancer. Cell Mol
Life Sci. 64:3201–3218. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weigelt B, Peterse JL and van't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carmichael A, Sami AS and Dixon JM: Breast
cancer risk among the survivors of atomic bomb and patients exposed
to therapeutic ionising radiation. Eur J Surg Oncol. 29:475–479.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wass J and Finer N: Action on obesity:
comprehensive care for all. Clin Med (Lond). 13:4–5. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lakhtakia R: Conspicuous consumption and
sedentary Living: Is this our legacy to our children? Sultan Qaboos
Univ Med J. 13:336–340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McKenzie F, Ellison-Loschmann L, Jeffreys
M, Firestone R, Pearce N and Romieu I: Cigarette smoking and risk
of breast cancer in a New Zealand Multi-Ethnic Case-Control Study.
PLoS One. 8:e631322013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee IM, Shiroma EJ, Lobelo F, Puska P,
Blair SN and Katzmarzyk PT; Lancet Physical Activity Series Working
Group, : Effect of physical inactivity on major non-communicable
diseases worldwide: An analysis of burden of disease and life
expectancy. Lancet. 380:219–229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fioretti F, Tavani A, Bosetti C, La
Vecchia C, Negri E, Barbone F, Talamini R and Franceschi S: Risk
factors for breast cancer in nulliparous women. Br J Cancer.
79:1923–1928. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sieri S, Krogh V, Bolelli G, Abagnato CA,
Grioni S, Pala V, Evangelista A, Allemani C, Micheli A, Tagliabue
G, et al: Sex hormone levels, breast cancer risk, and cancer
receptor status in postmenopausal Women: The ORDET Cohort. Cancer
Epidemiol Biomarkers Prev. 18:169–176. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Colombo N, van Gorp T, Parma G, Amant F,
Gatta G, Sessa C and Vergote I: Ovarian cancer. Crit Rev Oncol
Hematol. 60:159–179. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Virnig BA, Tuttle TM, Shamliyan T and Kane
RL: Ductal carcinoma in situ of the breast: A systematic review of
incidence, treatment, and outcomes. J Natl Cancer Inst.
102:170–178. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Claus EB, Schildkraut JM, Thompson WD and
Risch NJ: The genetic attributable risk of breast and ovarian
cancer. Cancer. 77:2318–2324. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lynch HT, Casey MJ, Snyder CL, Bewtra C,
Lynch JF, Butts M and Godwin AK: Hereditary ovarian carcinoma:
Heterogeneity, molecular genetics, pathology, and management. Mol
Oncol. 3:97–137. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Perry C and Phillps B: Quick Review:
Breast Cancer. Int J Oncol. 1:22001.
|
|
31
|
Bewtra C, Watson P, Conway T, Read-Hippee
C and Lynch HT: Hereditary ovarian cancer: A clinicopathological
study. Int J Gynecol Pathol. 11:180–187. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rubin SC, Blackwood MA, Bandera C,
Behbakht K, Benjamin I, Rebbeck TR and Boyd J: BRCA1, BRCA2, and
hereditary nonpolyposis colorectal cancer gene mutations in an
unselected ovarian cancer population: Relationship to family
history and implications for genetic testing. Am J Obstet Gynecol.
178:670–677. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Macdonald F, Ford CHJ and Casson AG:
Molecular Biology of Cancer. 2nd. BIOS Scientific; London: 2004
|
|
34
|
Economopoulou P, Dimitriadis G and Psyrri
A: Beyond BRCA: New hereditary breast cancer susceptibility genes.
Cancer Treat Rev. 41:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Watson IR, Takahashi K, Futreal PA and
Chin L: Emerging patterns of somatic mutations in cancer. Nat Rev
Genet. 14:703–718. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao D, Zhang F, Zhang W, He J, Zhao Y and
Sun J: Prognostic role of hormone receptors in ovarian cancer: A
systematic review and meta-analysis. Int J Gynecol Cancer.
23:25–33. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gusterson BA, Gelber RD, Goldhirsch A,
Price KN, Säve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam CM,
Golouh R, Reed R, et al: Prognostic importance of c-erbB-2
expression in breast cancer. International (Ludwig) Breast Cancer
Study Group. J Clin Oncol. 10:1049–1056. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Carter CL, Allen C and Henson DE: Relation
of tumor size, lymph node status and survival in 24,740 breast
cancer cases. Cancer. 63:181–187. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Prat J; FIGO Committee on Gynecologic
Oncology, : FIGO's staging classification for cancer of the ovary,
fallopian tube, and peritoneum: Abridged republication. J Gynecol
Oncol. 26:87–89. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Young RC, Walton LA, Ellenberg SS,
Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R and Major F
Jr: Adjuvant therapy in stage I and stage II epithelial ovarian
cancer. Results of two prospective randomized trials. N Engl J Med.
322:1021–1027. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schorge JO, McCann C and Del Carmen MG:
Surgical debulking of ovarian cancer: What difference does it make?
Rev Obstet Gynecol. 3:111–117. 2010.PubMed/NCBI
|
|
42
|
Ezzati M, Abdullah A, Shariftabrizi A, Hou
J, Kopf M, Stedman JK, Samuelson R and Shahabi S: Recent
advancements in prognostic factors of epithelial ovarian carcinoma.
Int Sch Res Notices. 2014:9535092014.PubMed/NCBI
|
|
43
|
Bristow RE, Tomacruz RS, Armstrong DK,
Trimble EL and Montz FJ: Survival effect of maximal cytoreductive
surgery for advanced ovarian carcinoma during the platinum Era: A
meta-analysis. J Clin Oncol. 20:1248–1259. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
McGuire WP, Hoskins WJ, Brady MF, Kucera
PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and Stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Malhotra GK, Zhao X, Band H and Band V:
Histological, molecular and functional subtypes of breast cancers.
Cancer Biol Ther. 10:955–960. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schwartz AM, Henson DE, Chen D and
Rajamarthandan S: Histologic grade remains a prognostic factor for
breast cancer regardless of the number of positive lymph nodes and
tumor Size: A study of 161 708 cases of breast cancer from the seer
program. Arch Pathol Lab Med. 138:1048–1052. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Harvey JM, Clark GM, Osborne CK and Allred
DC: Estrogen receptor status by immunohistochemistry is superior to
the ligand-binding assay for predicting response to adjuvant
endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1781.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fisher B, Redmond C, Fisher ER and Caplan
R: Relative worth of estrogen or progesterone receptor and
pathologic characteristics of differentiation as indicators of
prognosis in node negative breast cancer patients: findings from
National Surgical Adjuvant Breast and Bowel Project Protocol B-06.
J Clin Oncol. 6:1076–1087. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cheang MC, Treaba DO, Speers CH, Olivotto
IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks
CB, et al: Immunohistochemical detection using the new rabbit
monoclonal antibody sp1 of estrogen receptor in breast cancer is
superior to mouse monoclonal antibody 1d5 in predicting survival. J
Clin Oncol. 24:5637–5644. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tangjitgamol S, Manusirivithaya S,
Khunnarong J, Jesadapatarakul S and Tanwanich S: Expressions of
estrogen and progesterone receptors in epithelial ovarian cancer: A
clinicopathologic study. Int J Gynecol Cancer. 19:620–627. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lindgren PR, Cajander S, Bäckström T,
Gustafsson JÅ, Mäkelä S and Olofsson JI: Estrogen and progesterone
receptors in ovarian epithelial tumors. Mol Cell Endocrinol.
221:97–104. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fisher B, Jeong J-H, Anderson S and
Wolmark N: Treatment of axillary lymph node-negative, estrogen
receptor-negative breast cancer: Updated findings from national
surgical adjuvant breast and bowel project clinical trials. J Natl
Cancer Inst. 96:1823–1831. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Winer EP, Hudis C, Burstein HJ, Wolff AC,
Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J,
et al: American society of clinical oncology technology assessment
on the use of aromatase inhibitors as adjuvant therapy for
postmenopausal women with hormone receptor-positive breast cancer:
Status Report 2004. J Clin Oncol. 23:619–629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Slamon D, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Borg A, Tandon AK, Sigurdsson H, Clark GM,
Fernö M, Fuqua SA, Killander D and McGuire WL: HER-2/neu
Amplification Predicts Poor Survival in Node-positive Breast
Cancer. Cancer Res. 50:4332–4337. 1990.PubMed/NCBI
|
|
56
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cianfrocca M and Goldstein LJ: Prognostic
and Predictive Factors in Early-Stage Breast Cancer. Oncologist.
9:606–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Jönsson JM, Arildsen N Skovbjerg, Malander
S, Måsbäck A, Hartman L, Nilbert M and Hedenfalk I: Sex steroid
hormone receptor expression affects ovarian cancer survival. Transl
Oncol. 8:424–433. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tassi RA, Calza S, Ravaggi A, Bignotti E,
Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini
P, et al: Mammaglobin B is an independent prognostic marker in
epithelial ovarian cancer and its expression is associated with
reduced risk of disease recurrence. BMC Cancer. 9:2532009.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Berchuck A, Iversen ES, Lancaster JM,
Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M,
et al: Patterns of gene expression that characterize long-term
survival in advanced stage serous ovarian cancers. Clin Cancer Res.
11:3686–3696. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Barlin JN, Jelinic P, Olvera N, Bogomolniy
F, Bisogna M, Dao F, Barakat RR, Chi DS and Levine DA: Validated
gene targets associated with curatively treated advanced serous
ovarian carcinoma. Gynecol Oncol. 128:512–517. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yoshihara K, Tajima A, Komata D, Yamamoto
T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K,
et al: Gene expression profiling of advanced-stage serous ovarian
cancers distinguishes novel subclasses and implicates ZEB2 in tumor
progression and prognosis. Cancer Sci. 100:1421–1428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Guénard F, Labrie Y, Ouellette G,
Beauparlant C Joly, Simard J and Durocher F: INHERIT BRCAs:
Mutational analysis of the breast cancer susceptibility gene BRIP1
/BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families. J
Hum Genet. 53:579–591. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Nasi ML and Castiglione M:
Cyclooxygenase-2 (COX-2) a new prognostic and predictive factor for
ovarian cancer? Are all the criteria fulfilled? Ann Oncol.
13:1169–1171. 2002.PubMed/NCBI
|
|
65
|
Saslow D, Boetes C, Burke W, Harms S,
Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, et al:
American cancer society guidelines for breast screening with MRI as
an adjunct to mammography. CA Cancer J Clin. 57:75–89. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yu YH, Liang C and Yuan XZ: Diagnostic
value of vacuum-assisted breast biopsy for breast carcinoma: A
meta-analysis and systematic review. Breast Cancer Res Treat.
120:469–479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Board CNE: Ovarian Cancer-Additional
Resources. Journal 2016. 2012.
|
|
68
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics. CA Cancer J Clin. 59:225–249. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Guidelines NCCNN: Breast Cancer Version
2.2011 Journal. 2015, https://www.nccn.org/professionals/physician_gls/f_guidelines.aspNovember
23–2015
|
|
70
|
NCCN: Breast cancer-in situ (stage 0).
version 1. 2016, https://www.nccn.org/patients/guidelines/stage_0_breast/index.html#1/zNovember
23–2015
|
|
71
|
Perreard L, Fan C, Quackenbush JF, Mullins
M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K,
et al: Classification and risk stratification of invasive breast
carcinomas using a real-time quantitative RT-PCR assay. Breast
Cancer Res. 8:R232006. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Weigelt B, Horlings HM, Kreike B, Hayes
MM, Hauptmann M, Wessels LF, De Jong D, van de Vijver MJ, Van't
Veer LJ and Peterse JL: Refinement of breast cancer classification
by molecular characterization of histological special types. J
Pathol. 216:141–150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Markman M, Iseminger KA, Hatch KD,
Creasman WT, Barnes W and Dubeshter B: Tamoxifen in
platinum-refractory ovarian cancer: A gynecologic oncology group
ancillary report. Gynecol Oncol. 62:4–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Bowman A, Gabra H, Langdon SP, Lessells A,
Stewart M, Young A and Smyth JF: CA125 response is associated with
estrogen receptor expression in a phase II trial of letrozole in
ovarian cancer. Clin Cancer Res. 8:2233–2239. 2002.PubMed/NCBI
|
|
76
|
Konner J, Schilder RJ, DeRosa FA, Gerst
SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR and Aghajanian CA:
A phase II study of cetuximab/paclitaxel/carboplatin for the
initial treatment of advanced-stage ovarian, primary peritoneal, or
fallopian tube cancer. Gynecol Oncol. 110:140–145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Burger RA, Brady MF, Bookman MA, Fleming
GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE,
et al: Incorporation of Bevacizumab in the primary treatment of
ovarian cancer. N Engl J Med. 365:2473–2483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Markman M: Combination versus sequential
cytotoxic chemotherapy in recurrent ovarian cancer: Time for an
evidence-based comparison. Gynecol Oncol. 118:6–7. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Ozols RF: Systemic therapy for ovarian
cancer: Current status and new treatments. Semin Oncol. 33 2 Suppl
6:S3–S11. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Tagawa T, Morgan R, Yen Y and Mortimer J:
Ovarian Cancer: Opportunity for targeted therapy. J Oncol.
2012:6824802012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Mateo J, Moreno V, Gupta A, Kaye SB, Dean
E, Middleton MR, Friedlander M, Gourley C, Plummer R, Rustin G, et
al: An adaptive study to determine the optimal dose of the tablet
formulation of the PARP inhibitor olaparib. Target Oncol.
11:401–415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Tutt A, Robson M, Garber JE, Domchek SM,
Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler
RK, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in
patients with BRCA1 or BRCA2 mutations and advanced breast cancer:
A proof-of-concept trial. Lancet. 376:235–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Marchionni L, Wilson RF, Marinopoulos SS,
Wolff AC, Parmigiani G, Bass EB and Goodman SN: Impact of gene
expression profiling tests on breast cancer outcomes. Evid Rep
Technol Assess (Full Rep). 1–105. 2007.PubMed/NCBI
|
|
84
|
Marrone M, Stewart A and Dotson WD:
Clinical utility of gene-expression profiling in women with early
breast cancer: An overview of systematic reviews. Genet Med.
17:519–532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wildsmith SE and Elcock FJ: Microarrays
under the microscope. Mol Pathol. 54:8–16. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Maughan NJ, Lewis FA and Smith V: An
introduction to arrays. J Pathol. 195:3–6. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:pp. 10869–10874. 2001; View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Sørlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:pp.
8418–8423. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Sotiriou C, Neo SY, McShane LM, Korn EL,
Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET: Breast
cancer classification and prognosis based on gene expression
profiles from a population-based study. Proc Natl Acad Sci USA.
100:pp. 10393–10398. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Dai H, van't Veer L, Lamb J, He YD, Mao M,
Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, et al: A
cell proliferation signature is a marker of extremely poor outcome
in a subpopulation of breast cancer patients. Cancer Res.
65:4059–4066. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Ma XJ, Wang Z, Ryan PD, Isakoff SJ,
Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT,
et al: A two-gene expression ratio predicts clinical outcome in
breast cancer patients treated with tamoxifen. Cancer Cell.
5:607–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhao X, Li C, Paez JG, Chin K, Jänne PA,
Chen TH, Girard L, Minna J, Christiani D, Leo C, et al: An
Integrated view of copy number and allelic alterations in the
cancer genome using single nucleotide polymorphism arrays. Cancer
Res. 64:3060–3071. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Huang E, Cheng SH, Dressman H, Pittman J,
Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, et al: Gene
expression predictors of breast cancer outcomes. Lancet.
361:1590–1596. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
West M, Blanchette C, Dressman H, Huang E,
Ishida S, Spang R, Zuzan H, Olson JA Jr, Marks JR and Nevins JR:
Predicting the clinical status of human breast cancer by using gene
expression profiles. Proc Natl Acad Sci USA. 98:pp. 11462–11467.
2001; View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Chin K, DeVries S, Fridlyand J, Spellman
PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et
al: Genomic and transcriptional aberrations linked to breast cancer
pathophysiologies. Cancer Cell. 10:529–541. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
van de Vijver MJ, He YD, van't Veer LJ,
Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C,
Marton MJ, et al: A gene-expression signature as a predictor of
survival in breast cancer. N Engl J Med. 347:1999–2009. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
van 't Veer LJ, Dai H, van de Vijver MJ,
He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Naderi A, Teschendorff AE, Barbosa-Morais
NL, Pinder SE, Green AR, Powe DG, Robertson JFR, Aparicio S, Ellis
IO, Brenton JD and Caldas C: A gene-expression signature to predict
survival in breast cancer across independent data sets. Oncogene.
26:1507–1516. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Acharya CR, Hsu DS, Anders CK, Anguiano A,
Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee
S, et al: Gene expression signatures, clinicopathological features,
and individualized therapy in breast cancer. JAMA. 299:1574–1587.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM,
Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu
J, et al: Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet. 365:671–679.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Miller LD, Smeds J, George J, Vega VB,
Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET and Bergh
J: An expression signature for p53 status in human breast cancer
predicts mutation status, transcriptional effects, and patient
survival. Proc Natl Acad Sci USA. 102:pp. 13550–13555. 2005;
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Ciriello G, Gatza ML, Beck AH, Wilkerson
MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et
al: Comprehensive molecular portraits of invasive lobular breast
cancer. Cell. 163:506–519. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Desmedt C, Zoppoli G, Gundem G, Pruneri G,
Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D,
et al: Genomic characterization of primary invasive lobular breast
cancer. J Clin Oncol. 34:1872–1881. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Reis-Filho JS, Westbury C and Pierga JY:
The impact of expression profiling on prognostic and predictive
testing in breast cancer. J Clinl Pathol. 59:225–231. 2006.
View Article : Google Scholar
|
|
106
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Panel members: Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the St. gallen international expert consensus on the primary
therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Banerji S, Cibulskis K, Rangel-Escareno C,
Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY,
Sougnez C, Zou L, et al: Sequence analysis of mutations and
translocations across breast cancer subtypes. Nature. 486:405–409.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Kan Z, Jaiswal BS, Stinson J, Janakiraman
V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, et al:
Diverse somatic mutation patterns and pathway alterations in human
cancers. Nature. 466:869–873. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Robinson DR, Wu YM, Vats P, Su F, Lonigro
RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, et al:
Activating ESR1 mutations in hormone-resistant metastatic breast
cancer. Nat Genet. 45:1446–1451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Toy W, Shen Y, Won H, Green B, Sakr RA,
Will M, Li Z, Gala K, Fanning S, King TA, et al: ESR1
ligand-binding domain mutations in hormone-resistant breast cancer.
Nat Genet. 45:1439–1445. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A
multigene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Fumagalli D, Desmedt C, Ignatiadis M, Loi
S, Piccart M and Sotiriou C: Gene profiling assay and application:
The predictive role in primary therapy. J Natl Cancer Inst Monogr.
2011:124–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Fehrmann RS, Li XY, van der Zee AG, De
Jong S, Te Meerman GJ, de Vries EG and Crijns AP: Profiling Studies
in Ovarian Cancer: A Review. Oncologist. 12:960–966. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Lu KH, Patterson AP, Wang L, Marquez RT,
Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I,
et al: Selection of potential markers for epithelial ovarian cancer
with gene expression arrays and recursive descent partition
analysis. Clin Cancer Res. 10:3291–3300. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Konstantinopoulos PA, Spentzos D, Karlan
BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA and Cannistra
SA: Gene expression profile of BRCAness that correlates with
responsiveness to chemotherapy and with outcome in patients with
epithelial ovarian cancer. J Clinl Oncol. 28:3555–3561. 2010.
View Article : Google Scholar
|
|
118
|
Crijns AP, Fehrmann RS, De Jong S, Gerbens
F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de
Vries EG and van der Zee AG: Survival-related profile, pathways,
and transcription factors in ovarian cancer. PLoS Med. 6:e242009.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Bonome T, Levine DA, Shih J, Randonovich
M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC,
Boyd J and Birrer MJ: A gene signature predicting for survival in
suboptimally debulked patients with ovarian cancer. Cancer Res.
68:5478–5486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Kothandaraman N, Bajic VB, Brendan PN,
Huak CY, Keow PB, Razvi K, Salto-Tellez M and Choolani M: E2F5
status significantly improves malignancy diagnosis of epithelial
ovarian cancer. BMC Cancer. 10:642010. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Sawiris GP, Sherman-Baust CA, Becker KG,
Cheadle C, Teichberg D and Morin PJ: Development of a highly
specialized cDNA array for the study and diagnosis of epithelial
ovarian cancer. Cancer Res. 62:2923–2928. 2002.PubMed/NCBI
|
|
122
|
Resnick KE, Alder H, Hagan JP, Richardson
DL, Croce CM and Cohn DE: The detection of differentially expressed
microRNAs from the serum of ovarian cancer patients using a novel
real-time PCR platform. Gynecol Oncol. 112:55–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Chang H, Zhou X, Wang ZN, Song YX, Zhao F,
Gao P, Chiang Y and Xu HM: Increased expression of miR-148b in
ovarian carcinoma and its clinical significance. Mol Med Rep.
5:1270–1280. 2012.
|
|
124
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Shapira I, Oswald M, Lovecchio J, Khalili
H, Menzin A, Whyte J, Dos Santos L, Liang S, Bhuiya T, Keogh M, et
al: Circulating biomarkers for detection of ovarian cancer and
predicting cancer outcomes. Br J Cancer. 110:976–983. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Vecchione A, Belletti B, Lovat F, Volinia
S, Chiappetta G, Giglio S, Sonego M, Cirombella R, Onesti EC,
Pellegrini P, et al: A microRNA signature defines chemoresistance
in ovarian cancer through modulation of angiogenesis. Proc Natl
Acad Sci USA. 110:pp. 9845–9850. 2013; View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Jazaeri AA, Awtrey CS, Chandramouli GV,
Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK,
Birrer MJ, et al: Gene expression profiles associated with response
to chemotherapy in epithelial ovarian cancers. Clin Cancer Res.
11:6300–6310. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Hartmann LC, Lu KH, Linette GP, Cliby WA,
Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, et
al: Gene expression profiles predict early relapse in ovarian
cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res.
11:2149–2155. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Tothill RW, Tinker AV, George J, Brown R,
Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro
B, et al: Novel molecular subtypes of serous and endometrioid
ovarian cancer linked to clinical outcome. Clin Cancer Res.
14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Cancer Genome Atlas Research Network, .
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Konecny GE, Wang C, Hamidi H, Winterhoff
B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, et al:
Prognostic and therapeutic relevance of molecular subtypes in
high-grade serous ovarian cancer. J Natl Cancer Inst. 106:pii:
dju2492014. View Article : Google Scholar
|
|
132
|
Liu J and Matulonis UA: New Strategies in
Ovarian Cancer: Translating the molecular complexity of ovarian
cancer into treatment advances. Clin Cancer Res. 20:5150–5156.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Secord AA, Nixon AB and Hurwitz HI: The
search for biomarkers to direct antiangiogenic treatment in
epithelial ovarian cancer. Gynecol Oncol. 135:349–358. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Wang C, Winterhoff BJ, Kalli KR, Block MS,
Armasu SM, Larson MC, Chen HW, Keeney GL, Hartmann LC, Shridhar V,
et al: Expression signature distinguishing two tumour transcriptome
classes associated with progression-free survival among rare
histological types of epithelial ovarian cancer. Br J Cancer.
114:1412–1420. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Freitas S, Moore DH, Michael H and Kelley
MR: Studies of Apurinic/Apyrimidinic Endonuclease/ref-1 Expression
in Epithelial Ovarian Cancer. Correlations with tumor progression
and platinum resistance. Clin Cancer Res. 9:4689–4694.
2003.PubMed/NCBI
|
|
136
|
Hilton JL, Geisler JP, Rathe JA,
Hattermann-Zogg MA, DeYoung B and Buller RE: Inactivation of BRCA1
and BRCA2 in Ovarian Cancer. J Natl Cancer Inst. 94:1396–1406.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Prat A, Ellis MJ and Perou CM: Practical
implications of gene-expression-based assays for breast
oncologists. Nat Rev Clin Oncol. 9:48–57. 2012. View Article : Google Scholar
|
|
138
|
Al-Moundhri MS, Al-Ansari A, Al-Mawali K
and Al-Bahrani B: BRCA1 gene Molecular Alterations in Omani Breast
Cancer Patients. Gulf J Oncolog. 1:45–51. 2013.PubMed/NCBI
|
|
139
|
Cantor SB, Bell DW, Ganesan S, Kass EM,
Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA and
Livingston DM: BACH1, a Novel Helicase-like Protein, Interacts
Directly with BRCA1 and Contributes to Its DNA Repair Function.
Cell. 105:149–160. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Lee AD: Structural rearrangements in DNA
repair genes in breast cancer. University of Pittsburgh;
Pittsburgh: 2013
|
|
141
|
Li X, Ohgi KA, Zhang J, Krones A, Bush KT,
Glass CK, Nigam SK, Aggarwal AK, Maas R, Rose DW and Rosenfeld MG:
Eya protein phosphatase activity regulates Six1-Dach-Eya
transcriptional effects in mammalian organogenesis. Nature.
426:247–254. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Pandey RN, Rani R, Yeo EJ, Spencer M, Hu
S, Lang RA and Hegde RS: The Eyes Absent phosphatase-transactivator
proteins promote proliferation, transformation, migration, and
invasion of tumor cells. Oncogene. 29:3715–3722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Wu K, Li Z, Cai S, Tian L, Chen K, Wang J,
Hu J, Sun Y, Li X, Ertel A and Pestell RG: EYA1 phosphatase
function is essential to drive breast cancer cell proliferation
through Cyclin D1. Cancer Res. 73:4488–4499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Apiou F, Flagiello D, Cillo C, Malfoy B,
Poupon MF and Dutrillaux B: Fine mapping of human HOX gene
clusters. Cytogenet Cell Genet. 73:114–115. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Bhatlekar S, Fields JZ and Boman BM: HOX
genes and their role in the development of human cancers. J Mol Med
(Berl). 92:811–823. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Fischbach NA, Rozenfeld S, Shen W, Fong S,
Chrobak D, Ginzinger D, Kogan SC, Radhakrishnan A, Le Beau MM,
Largman C and Lawrence HJ: HOXB6 overexpression in murine bone
marrow immortalizes a myelomonocytic precursor in vitro and causes
hematopoietic stem cell expansion and acute myeloid leukemia in
vivo. Blood. 105:1456–1466. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Liu YJ, Zhu Y, Yuan HX, Zhang JP, Guo JM
and Lin ZM: Overexpression of HOXC11 homeobox gene in clear cell
renal cell carcinoma induces cellular proliferation and is
associated with poor prognosis. Tumor Biol. 36:2821–2829. 2015.
View Article : Google Scholar
|
|
148
|
Shah N and Sukumar S: The Hox genes and
their roles in oncogenesis. Nat Rev Cancer. 10:361–371. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Chen KN, Gu ZD, Ke Y, Li JY, Shi XT and Xu
GW: Expression of 11 HOX Genes Is deregulated in esophageal
squamous cell carcinoma. Clin Cancer Res. 11:1044–1049.
2005.PubMed/NCBI
|
|
150
|
Vider BZ, Zimber A, Chastre E, Gespach C,
Halperin M, Mashiah P, Yaniv A and Gazit A: Deregulated Expression
of homeobox-containing genes, HOXB6, B8, C8, C9 and Cdx-1, in human
colon cancer cell lines. Biochem Biophys Res Commun. 272:513–518.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Tait DL, Zhang J, Gurlov S, McKinney K,
Vachris J, Mougeot JLC, Wagstaff JE and Bahrani-Mostafav Z:
Differential expression of Hox genes in ovarian cancer. Cancer Res.
65:845–846. 2005.
|
|
152
|
Stone B, Schummer M, Paley PJ, Thompson L,
Stewart J, Ford M, Crawford M, Urban N, O'Briant K and Nelson BH:
Serologic analysis of ovarian tumor antigens reveals a bias toward
antigens encoded on 17q. Int J Cancer. 104:73–84. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Kelly Z, Moller-Levet C, McGrath S,
Butler-Manuel S, Madhuri T Kavitha, Kierzek AM, Pandha H, Morgan R
and Michael A: The prognostic significance of specific HOX gene
expression patterns in ovarian cancer. Int J Cancer. 139:1608–1617.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Shang B, Gao A, Pan Y, Zhang G, Tu J, Zhou
Y, Yang P, Cao Z, Wei Q, Ding Y, et al: CT45A1 acts as a new
proto-oncogene to trigger tumorigenesis and cancer metastasis. Cell
Death Dis. 5:e12852014. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Vider BZ, Zimber A, Hirsch D, Estlein D,
Chastre E, Prevot S, Gespach C, Yaniv A and Gazit A: Human
colorectal carcinogenesis is associated with deregulation of
homeobox gene expression. Biochem Biophys Res Commun. 232:742–748.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Castronovo V, Kusaka M, Chariot A, Gielen
J and Sobel M: Homeobox genes: Potential candidates for the
transcriptional control of the transformed and invasive phenotype.
Biochem Pharmacol. 47:137–143. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Green KJ and Simpson CL: Desmosomes: New
Perspectives on a Classic. J Invest Dermatol. 127:2499–2515. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Pang H, Rowan BG, Al-Dhaheri M and Faber
LE: Epidermal growth factor suppresses induction by progestin of
the adhesion protein desmoplakin in T47D breast cancer cells.
Breast Cancer Res. 6:R239–R245. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
159
|
Yang L, Chen Y, Cui T, Knösel T, Zhang Q,
Albring KF, Huber O and Petersen I: Desmoplakin acts as a tumor
suppressor by inhibition of the Wnt/β-catenin signaling pathway in
human lung cancer. Carcinogenesis. 33:1863–1870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Green KJ, Stappenbeck TS, Noguchi S, Oyasu
R and Nilles LA: Desmoplakin expression and distribution in
cultured rat bladder epithelial cells of varying tumorigenic
potential. Exp Cell Res. 193:134–143. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Hiraki A, Shinohara M, Ikebe T, Nakamura
S, Kurahara S and Garrod DR: Immunohistochemical staining of
desmosomal components in oral squamous cell carcinomas and its
association with tumour behaviour. Br J Cancer. 73:1491–1497. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Davies EL, Gee JMW, Cochrane RA, Jiang WG,
Sharma AK, Nicholson RI and Mansel RE: The immunohistochemical
expression of desmoplakin and its role in vivo in the progression
and metastasis of breast cancer. Eur J Cancer. 35:902–907. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Peck JW, Oberst M, Bouker KB, Bowden E and
Burbelo PD: The RhoA-binding protein, Rhophilin-2, regulates actin
cytoskeleton organization. J Biol Chem. 277:43924–43932. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
He D, Ma L, Feng R, Zhang L, Jiang Y,
Zhang Y and Liu G: Analyzing large-scale samples highlights
significant association between rs10411210 polymorphism and
colorectal cancer. Biomed Pharmacother. 74:164–168. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Wu K, Zhang X, Li F, Xiao D, Hou Y, Zhu S,
Liu D, Ye X, Ye M, Yang J, et al: Frequent alterations in
cytoskeleton remodelling genes in primary and metastatic lung
adenocarcinomas. Nat Commun. 6:101312015. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Danussi C, Akavia UD, Niola F, Jovic A,
Lasorella A, Pe'er D and Iavarone A: RHPN2 drives mesenchymal
transformation in malignant glioma by triggering RhoA activation.
Cancer Res. 73:5140–5150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Cao J, Ge MH and Ling ZQ: Fbxw7 Tumor
Suppressor: A vital regulator contributes to human tumorigenesis.
Medicine (Baltimore). 95:e24962016. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Yumimoto K, Akiyoshi S, Ueo H, Sagara Y,
Onoyama I, Ueo H, Ohno S, Mori M, Mimori K and Nakayama KI: F-box
protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous
manner. J Clin Invest. 125:621–635. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Wang Z, Liu P, Inuzuka H and Wei W: Roles
of F-box proteins in cancer. Nat Rev Cancer. 14:233–247. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Busino L, Millman SE, Scotto L, Kyratsous
CA, Basrur V, O'Connor O, Hoffmann A, Elenitoba-Johnson KS and
Pagano M: Fbxw7α- and GSK3-mediated degradation of p100 is a
pro-survival mechanism in multiple myeloma. Nat Cell Biol.
14:375–385. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Jardim DL, Wheler JJ, Hess K, Tsimberidou
AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN,
et al: FBXW7 mutations in patients with advanced cancers: clinical
and molecular characteristics and outcomes with mTOR inhibitors.
PLoS One. 9:e893882014. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Welcker M and Clurman BE: FBW7 ubiquitin
ligase: A tumour suppressor at the crossroads of cell division,
growth and differentiation. Nat Rev Cancer. 8:83–93. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Bellocq J and Magro G: Fibroepithelial
tumorsTavassoli FA and Devilee P: World Health Organization
Classification of Tumors: Tumors of the Breast and Female Genital
Organs. IARC; pp. 99–103. Lyon: 2003
|
|
174
|
Koshiyama M, Matsumura N and Konishi I:
Recent Concepts of Ovarian Carcinogenesis: Type I and Type II.
Biomed Res Int. 2014:9342612014. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Cho KR and Shih IeM: Ovarian Cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Magnifico A, Albano L, Campaner S,
Campiglio M, Pilotti S, Ménard S and Tagliabue E: Protein kinase
Clpha determines HER2 fate in breast carcinoma cells with HER2
protein overexpression without gene amplification. Cancer Res.
67:5308–5317. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Auersperg N, Maines-Bandiera SL and Dyck
HG: Ovarian carcinogenesis and the biology of ovarian surface
epithelium. J Cell Physiol. 173:261–265. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Auersperg N, Edelson MI, Mok SC, Johnson
SW and Hamilton TC: The biology of ovarian cancer. Semin Oncol.
25:281–304. 1998.PubMed/NCBI
|
|
179
|
Ideka K and Inoue S: Estrogen receptors
and their downstream targets in cancer. Arch Histol Cytol.
67:435–442. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Issa R, Lebeau A, Grob T, Holst F, Moch H,
Terracciano L, Choschzick M, Sauter G and Simon R: Estrogen
receptor gene amplification occurs rarely in ovarian cancer. Mod
Pathol. 22:191–196. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Eckert L, Repasky GA, Ulkü AS, McFall A,
Zhou H, Sartor CI and Der CJ: Involvement of Ras activation in
human breast cancer cell signaling, invasion, and anoikis. Cancer
Res. 64:4585–4592. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Aunoble B, Sanches R, Didier E and Bignon
YJ: Major oncogenes and tumor suppressor genes involved in
epithelial ovarian cancer (review). Int J Oncol. 3:567–576.
2000.
|
|
183
|
Liu J, Yang G, Thompson-Lanza JA, Glassman
A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, et
al: A genetically defined model for human ovarian cancer. Cancer
Res. 64:1655–1663. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Liao D and Dickson RB: c-Myc in breast
cancer. Endocr Relat Cancer. 7:143–164. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Chen CH, Shen J, Lee WJ and Chow SN:
Overexpression of cyclin D1 and c-Myc gene products in human
primary epithelial ovarian cancer. Int J Gynecol Cancer.
15:878–883. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Arnold A and Papanikolaou A: Cyclin D1 in
breast cancer pathogenesis. J Clin Oncol. 23:4215–4224. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Worsley SD, Ponder BA and Davies BR:
Overexpression of Cyclin D1 in epithelial ovarian cancers. Gynecol
Oncol. 64:189–195. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Petrucelli N, Daly MB and Feldman GL:
Hereditary Breast and Ovarian Cancer due to Mutations in BRCA1 and
BRCA2. Genet Med. 12:245–259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Birch J, Blair V, Kelsey AM, Evans DG,
Harris M, Tricker KJ and Varley JM: Cancer phenotype correlates
with constitutional TP53 genotype in families with the Li-Fraumeni
syndrome. Oncogene. 17:1061–1068. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Menendez D, Inga A and Resnick MA: The
expanding universe of p53 targets. Nat Rev Cancer. 9:724–737. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Khan S, Kumagai T, Vora J, Bose N, Sehgal
I, Koeffler PH and Bose S: PTEN promoter is methylated in a
proportion of invasive breast cancers. Int J Cancer. 112:407–410.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Garcia JM, Silva JM, Dominguez G, Gonzalez
R, Navarro A, Carretero L, Provencio M, España P and Bonilla F:
Allelic loss of the PTEN region (10q23) in breast carcinomas of
poor pathophenotype. Breast Cancer Res Treat. 57:237–243. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Petrocelli T and Slingerland JM: PTEN
deficiency: A role in mammary carcinogenesis. Breast Cancer Res.
3:356–360. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
195
|
Ross J, Linette GP, Stec J, Clark E, Ayers
M, Leschly N, Symmans WF, Hortobagyi GN and Pusztai L: Breast
cancer biomarkers and molecular medicine: part II. Expert Rev Mol
Diagn. 4:169–188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Hashiguchi Y, Tsuda H, Yamamoto K, Inoue
T, Ishiko O and Ogita S: Combined analysis of p53 and RB pathways
in epithelial ovarian cancer. Hum Pathol. 32:988–996. 2001.
View Article : Google Scholar : PubMed/NCBI
|
